Real-World IgAN: A Case-Based Approach to Maximizing Kidney Preservation
An De Vriese, MD, PhD
Muh Geot Wong, MBBS, PhD
The Critical Interplay: CKD, HF, and HyperkaleAmia
James Burton, DM, FRCP
Javed Butler, MD
Ellie Kelepouris, MD, FACP, FAHA
Patrick Rossignol, MD, PhD
Optimizing Hyperkalemia Management: Clinical Implications and Risk Assessment
Javed Butler, MD, MPH, MBA
Implementing Potassium Binders: Practical Dosing and Long-Term Follow Up
Guidelines Update: RAASi/MRA Therapy in CKD and HF Management
Optimizing RAASi/MRA Therapy in Patients with Heart Failure, CKD, and Hyperkalemia: A Microlearning Curriculum Approach
Potassium Binders in Practice: Clinical Trial Evidence
Potassium Binders: Safety Comes First!
Difelikefalin: Managing CKD-aP for Improved Quality of Life
Jörg Latus, MD
IgA Nephropathy Updates: Evolving Guidelines and Practical Strategies
Jürgen Floege, MD
Practical Strategies for Optimizing Outcomes in Patients with Iron Deficiency and Heart Failure
Robert J. Mentz, MD, FHFSA, FACC
Piotr Ponikowski, MD, PhD, FESC, FHFA
FAIR-HF2 Trial: Ferric Carboxymaltose Assessment of Morbidity and Mortality in Patients with Iron Deficiency and Chronic Heart Failure
Stefan D. Anker, MD, PhD
Mahir Karakas, MD, PhD, MBA
Improving CKD Patient Outcomes with SGLT2 Inhibitors
Gates B. Colbert, MD
Incorporating Targeted Therapies in Treatment Planning for AAV
David Jayne, MD
Bernhard Hellmich, MD
Achieving Success in IgAN & FSGS
Siân Griffin, MD, PhD
Loreto Gesualdo, MD, FERA
Directed Relief in CKD-aP: Linking Targeted Therapy to Clinical Outcomes
Thilo Krüger, MD, PhD
Steven Fishbane, MD
Lucio Manenti, MD, PhD
Loading...
NEW FEATURES:
Tell us what you think by using our Feedback button
We're glad to see you're enjoying Global Kidney Academy… but how about a more personalized experience?
Press cancel to remain on Global Kidney Academy. Press the link below or the continue button to keep going.